Pharmaceutical Grade An2728 Intermediate COA Specifications
- Comprehensive Certificate of Analysis (COA) ensures pharmaceutical grade compliance.
- Advanced HPLC and NMR testing validates synthesis route efficiency.
- Reliable bulk supply from NINGBO INNO PHARMCHEM CO.,LTD. for global manufacturers.
The production of high-quality dermatological therapeutics relies heavily on the integrity of key starting materials. 4-(4-Bromo-3-(hydroxymethyl)phenoxy)benzonitrile, identified by CAS 906673-45-8, serves as a critical precursor in the manufacturing process of non-steroidal phosphodiesterase-4 inhibitors. As a leading global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. prioritizes technical transparency and chemical consistency. This document outlines the essential Certificate of Analysis (COA) specifications required for this Crisaborole Intermediate, ensuring that downstream API synthesis meets rigorous regulatory standards.
Procurement teams and quality assurance managers must verify that the AN2728 Intermediate supplied meets strict purity thresholds. Variations in impurity profiles can significantly impact the efficacy and safety of the final topical formulation. Therefore, understanding the technical parameters within the COA is vital for maintaining supply chain integrity.
Understanding COA Requirements for Pharma Grade
A robust COA for 4-(4-Bromo-3-(hydroxymethyl)phenoxy)benzonitrile must extend beyond simple assay percentages. It should provide a detailed breakdown of related substances, residual solvents, and physical characteristics. For pharmaceutical grade materials, the assay typically must exceed 98.0% to 99.0%, depending on the specific customer agreement. The presence of the bromo and hydroxymethyl functional groups requires careful monitoring to prevent degradation during storage or transport.
Key parameters included in a comprehensive COA include:
- Appearance: White to off-white crystalline powder.
- Assay (HPLC): Not less than 98.5% on an anhydrous basis.
- Related Substances: Individual impurities not more than 0.10%; total impurities not more than 0.50%.
- Loss on Drying: Not more than 0.50%.
- Residual Solvents: Compliant with ICH Q3C guidelines.
When evaluating suppliers, it is crucial to assess their capability to maintain consistent quality across large batches. When sourcing high-purity industrial purity, buyers should demand batch-specific chromatograms that demonstrate the absence of critical starting materials or side products from the etherification step.
HPLC and NMR Testing Methodologies
Verification of the chemical structure and purity level relies on sophisticated analytical techniques. High-Performance Liquid Chromatography (HPLC) is the primary method for quantifying the assay and detecting related substances. The synthesis route for this molecule often involves nucleophilic substitution, which can generate specific byproducts. A validated HPLC method must be able to separate the main peak from these potential impurities with a resolution factor of greater than 2.0.
Proton Nuclear Magnetic Resonance (1H NMR) and Carbon-13 NMR (13C NMR) are utilized to confirm the molecular structure. These spectroscopic methods ensure that the 2-bromo-5-(4-cyanophenoxy)benzyl alcohol structure is correctly formed without isomeric contamination. The presence of the nitrile group and the aromatic protons provides distinct signals that must match reference standards. Additionally, mass spectrometry (LC-MS) is often employed to confirm the molecular weight and identify any unknown impurities that may arise during the manufacturing process.
Typical Specification Table
| Test Parameter | Specification Limit | Typical Result |
|---|---|---|
| Identification (IR/NMR) | Conforms to Structure | Conforms |
| Assay (HPLC Area %) | NLT 98.5% | 99.2% |
| Single Largest Impurity | NMT 0.10% | 0.05% |
| Total Impurities | NMT 0.50% | 0.18% |
| Loss on Drying | NMT 0.50% | 0.12% |
| Heavy Metals | NMT 10 ppm | < 5 ppm |
Regulatory Compliance and Documentation Support
Compliance with international regulatory standards is non-negotiable for intermediates used in human therapeutics. Suppliers must adhere to Good Manufacturing Practices (GMP) appropriate for fine chemicals. Documentation support should include Stability Data, Method Validation Reports, and Drug Master Files (DMF) where applicable. The chemical, also known generically as Bromohydroxymethylphenoxybenzonitrile, must be tracked through a robust quality management system to ensure traceability from raw materials to the finished intermediate.
For companies engaged in custom synthesis, the ability to modify specifications based on specific process needs is a significant advantage. Whether the requirement is for clinical trial material or commercial scale production, the supplier must demonstrate flexibility without compromising safety or quality. Residual solvent analysis is particularly critical, as solvents used in the crystallization step must be reduced to acceptable limits defined by regulatory bodies.
Commercial Viability and Bulk Procurement
Beyond technical specifications, commercial terms play a pivotal role in supplier selection. Bulk price stability and supply chain reliability are essential for long-term project planning. NINGBO INNO PHARMCHEM CO.,LTD. offers scalable production capacities that align with the growing demand for dermatological treatments. Efficient logistics and proper packaging ensure that the hygroscopic nature of certain intermediates does not compromise quality during transit.
Investing in a qualified supply partner reduces the risk of production delays and regulatory setbacks. By prioritizing detailed COA specifications and rigorous testing protocols, pharmaceutical companies can ensure the consistent quality of their final products. The integration of advanced analytical data with reliable manufacturing capabilities defines the standard for modern pharmaceutical intermediate supply.